CompanyGraph
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleMarket cap is $1.47B, above the global median of $1.15B
- FinancialsAltman Z-Score 4.49: safe zone
- Interpretations1 currently firing — 1
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
9.86BCNY1.47B · vs all stocks (USD)
Trailing P/E
87.83xvs Biotechnology peers
Revenue (TTM)
1.42BCNY211.39M · vs all stocks (USD)
Profit Margin
7.74%vs Biotechnology peers
Beta
-0.1620xvs all stocks
52-Week Change
-26.03%vs all stocks
Market Capitalization
9.86BCNY1.47B · vs all stocks (USD)
Enterprise Value
7.71BCNY1.15B · vs all stocks (USD)
Trailing P/E
87.83xvs Biotechnology peers
Forward P/E
47.91xvs Biotechnology peers
PEG Ratio
-5.27xvs Biotechnology peers
Price to Sales (TTM)
6.94xvs Biotechnology peers
Price to Book (MRQ)
2.58xvs Biotechnology peers
Enterprise to Revenue
5.42xvs Biotechnology peers
Enterprise to EBITDA
32.57xvs Biotechnology peers
Gross Margin
69.57%vs Biotechnology peers
Profit Margin
7.74%vs Biotechnology peers
Operating Margin
9.49%vs Biotechnology peers
Return on Assets (TTM)
1.79%vs Biotechnology peers
Return on Equity (TTM)
2.74%vs Biotechnology peers
Revenue (TTM)
1.42BCNY211.39M · vs all stocks (USD)
Revenue per Share (TTM)
3.09CNYUpdated Aug 20, 2026Quarterly Revenue Growth
-9.50%vs Biotechnology peers
Gross Profit (TTM)
977.34MCNY145.34M · vs all stocks (USD)
EBITDA (TTM)
360.79MCNY53.65M · vs all stocks (USD)
Net Income (TTM)
110.05MCNY16.36M · vs all stocks (USD)
Quarterly Earnings Growth (YoY)
-13.50%vs Biotechnology peers
Operating Cash Flow (TTM)
295.38MCNY43.93M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
187.34MCNY27.86M · vs all stocks (USD)
Payout Ratio
0.00%vs Biotechnology peers
Minority Interest (Equity)
48.24MCNYFY2025 · Dec 31, 2025Revenue
1.45BCNYFY2025 · Dec 31, 2025Cost of Goods Sold
438.80MCNYFY2025 · Dec 31, 2025Gross Profit
1.02BCNYFY2025 · Dec 31, 2025Operating Income
196.55MCNY29.23M · vs all stocks (USD)
Pre-tax Income
174.45MCNYFY2025 · Dec 31, 2025Income Tax Expense
70.92MCNYFY2025 · Dec 31, 2025Net Income
103.53MCNYFY2025 · Dec 31, 2025EBIT
196.55MCNYFY2025 · Dec 31, 2025EBITDA (Income Statement)
360.79MCNYFY2025 · Dec 31, 2025Research & Development
149.01MCNYFY2025 · Dec 31, 2025Selling, General & Administrative
369.38MCNYFY2025 · Dec 31, 2025Other Operating Expenses
27.59MCNYFY2025 · Dec 31, 2025Non-operating Interest Income
17.90MCNYFY2025 · Dec 31, 2025EPS (Basic)
0.2500CNYFY2025 · Dec 31, 2025EPS (Diluted)
0.2500CNYFY2025 · Dec 31, 2025Basic Shares Outstanding
455.32MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
455.32MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
103.53MCNYFY2025 · Dec 31, 2025Minority Interests (P&L)
10.30MCNYFY2025 · Dec 31, 2025Preferred Stock Dividends
0.00CNYFY2025 · Dec 31, 2025Operating Cash Flow
137.75MCNYFY2025 · Dec 31, 2025Free Cash Flow
88.50MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
1.01BCNYFY2025 · Dec 31, 2025Starting Profit (CF Statement)
103.53MCNYFY2025 · Dec 31, 2025Other Non-cash Items
21.69MCNYFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
-20.20MCNYFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
32.73MCNYFY2025 · Dec 31, 2025Capital Expenditures
-49.25MCNYFY2025 · Dec 31, 2025Purchase of Investments
-3.18BCNYFY2025 · Dec 31, 2025Sale of Investments
2.48BCNYFY2025 · Dec 31, 2025Net Investing Cash Flow
-747.85MCNYFY2025 · Dec 31, 2025Other Financing Charges
-68.86MCNYFY2025 · Dec 31, 2025Net Financing Cash Flow
-68.86MCNYFY2025 · Dec 31, 2025Shares Outstanding
467.95MSharesUpdated Aug 20, 2026Float Shares
344.25MSharesUpdated Aug 20, 2026% Held by Insiders
29.75%vs all stocks
% Held by Institutions
5.42%vs all stocks
Total Cash (MRQ)
1.73BCNY257.99M · vs all stocks (USD)
Total Cash per Share (MRQ)
3.81CNYUpdated Aug 20, 2026Total Debt (MRQ)
85.92MCNY12.78M · vs all stocks (USD)
Total Debt to Equity (MRQ)
0.0228xvs Biotechnology peers
Current Ratio (MRQ)
1.88xvs Biotechnology peers
Book Value per Share (MRQ)
8.16CNYUpdated Aug 20, 2026Total Assets
5.29BCNY787.01M · vs all stocks (USD)
Total Current Assets
2.66BCNYFY2025 · Dec 31, 2025Total Liabilities
1.54BCNYFY2025 · Dec 31, 2025Total Non-current Assets
2.64BCNYFY2025 · Dec 31, 2025Total Non-current Liabilities
79.51MCNYFY2025 · Dec 31, 2025Total Current Liabilities
1.46BCNYFY2025 · Dec 31, 2025Cash
1.01BCNYFY2025 · Dec 31, 2025Cash Equivalents
1.95MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents
1.01BCNYFY2025 · Dec 31, 2025Other Short-term Investments
712.05MCNYFY2025 · Dec 31, 2025Accounts Receivable
605.87MCNYFY2025 · Dec 31, 2025Inventory
230.23MCNYFY2025 · Dec 31, 2025Accounts Payable
97.45MCNYFY2025 · Dec 31, 2025Short-term Debt
21.39MCNYFY2025 · Dec 31, 2025Other Current Liabilities
59.52MCNYFY2025 · Dec 31, 2025Long-term Debt
47.28MCNYFY2025 · Dec 31, 2025Common Stock (Book)
467.95MCNYFY2025 · Dec 31, 2025Retained Earnings
-103.25MCNYFY2025 · Dec 31, 2025Total Shareholders' Equity
3.75BCNY558.38M · vs all stocks (USD)
Treasury Stock
200.03MCNYFY2025 · Dec 31, 202552-Week Low
16.24CNYUpdated Aug 20, 202652-Week High
32.99CNYUpdated Aug 20, 202652-Week Change
-26.03%vs all stocks
Beta
-0.1620xvs all stocks
50-Day MA
18.74CNYUpdated Aug 20, 2026200-Day MA
24.57CNYUpdated Aug 20, 2026Avg 10-Day Volume
24.96MSharesUpdated Aug 20, 2026Avg 30-Day Volume
15.15MSharesUpdated Aug 20, 2026Diluted EPS (TTM)
0.2400CNYUpdated Aug 20, 20261 interpretation currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsIs this company financially stable?
Multi-Year Debt Decrease With Cash Near Total Debt And Equity
Long-term debt down in each of four years, and cash now covers most or all of what is left.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Structural Tensions
High gross margins eroded by operating costsNotable
Gross Margin: 0.70Profit Margin: 0.08
Financial Health
Altman Z-Score 4.49: safe zoneNotable
Altman Z-Score: 4.49
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Market cap is $1.47B, above the global median of $1.15BNotable
Market cap (USD): 1,466,929,362.395Global Median: 1,146,734,693.424
Levered free cash flow is $27.86M, above the global median of $16.24MNotable
Levered free cash flow (USD): 27,858,929.288Global Median: 16,239,329.704
Companies that share the same coordination system — how they create, deliver, or capture value.
Beijing Hotgen Biotech Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Concord Biotech Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Inspire Medical Systems, Inc.
Tier 1ProductionApproval-Gated PipelineRule
Shandong Xinhua Pharmaceutical Company Limited
Tier 1ProductionApproval-Gated PipelineRuleFlow
HBM Holdings Limited
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
KalVista Pharmaceuticals Inc.
Tier 1ProductionApproval-Gated PipelineRule
Integra LifeSciences Holdings Corporation
Tier 1ProductionApproval-Gated PipelineRuleFlow
Zhejiang Jolly Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Olix Pharmaceuticals Inc.
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
Pacific Shuanglin Bio-Pharmacy Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Companies that share active interpretations — structural patterns currently present in both stocks.
Nanjing Xinjiekou Department Store Co. Ltd.
1 interpretationMulti-Year Debt Decrease With Cash Near Total Debt And Equity
Wave Life Sciences Ltd.
1 interpretationMulti-Year Debt Decrease With Cash Near Total Debt And Equity
SM Entertainment Co., Ltd.
1 interpretationMulti-Year Debt Decrease With Cash Near Total Debt And Equity